Request an Appointment
More Ways to Schedule
Pay Your Bill
Find a Doctor
Trauma & Surgical Critical Care
Cancer Care Locations
Heart Care Locations
Research & Clinical Trials
Health Info A-Z
Classes & Events
Carolinas Health Magazine
Informacion de la salud de busqueda (en Espanol)
Pay Your Bill
Register for a Class
Carolinas Mobile App
Cabarrus College of Health Sciences
Carolinas College of Health Sciences
Center for Advanced Practice
Center for Faculty Excellence
Center for Life Support Education
Carolinas Simulation Center
Center for Prehospital Medicine
Mercy School of Nursing
School of Nurse Anesthesia
UNC School of Medicine Charlotte Campus
Research and Clinical Trials
To assess the incidence of drug-related adverse events of Grade 3 or higher during the induction period of Ipilimumab.
Hall, James B
The purpose of this study is to compare progression-free survival (PFS) (based upon investigator assessment using RECIST v1.1) in participants with platinum-resistant ovarian cancer who receive combination therapy with EC145 and pegylated liposomal doxorubicin (EC145+PLD) with that in participants who receive PLD and placebo.
This randomized phase II trial studies how well giving cabozantinib or paclitaxel works in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet kn
This randomized phase III trial is studying giving carboplatin, paclitaxel and gemcitabine together with or without bevacizumab after surgery to see how well it works in treating patients with recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer.
This randomized phase III trial is studying diet and physical activity changes to see how well they work compared with usual care in improving progression-free survival of patients with previously treated stage II, stage III, or stage IV ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
This randomized phase III trial is studying giving paclitaxel together with carboplatin to see how well it works compared with giving paclitaxel together with ifosfamide in treating patients with newly diagnosed persistent or recurrent uterine or ovarian cancer.
This is studying how well giving temsirolimus, carboplatin, and paclitaxel together as first-line therapy works in treating patients with newly diagnosed stage III or stage IV clear cell ovarian cancer.
This trial studies the chemotherapy toxicity on quality of life in older patients with stage I, stage II, stage III, or stage IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer.
Primary: Estimate progression free survival hazard ration and determing frequency and severity of adverse events associated with the treatment of weekly paclitaxel vs. weekly paclitaxel and REOLYSIN® treatment.
The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.
This study compares the overall survival of patients treated with VTX-2337 plus pegylated liposomal doxorubicin (PLD) versus those treated with PLD alone in women with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.
About Carolinas HealthCare System
Who We Are
Corporate Financial Information
Diversity and Inclusion
Pay Your Bill
Quality Report Card
Join Carolinas HealthCare System
Connect with Us
© 2013 Carolinas HealthCare System 800-821-1535 |